Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
Access Pharmaceuticals to Present at Jesup & Lamont 2009
Access to Provide Details on MuGard Launch in Europe
DALLAS, July 22, 2009 /PRNewswire-FirstCall/ --ACCESS
PHARMACEUTICALS, INC. (OTC:ACCP) (BULLETIN BOARD: ACCP) announced
today that Jeffrey B. Davis, President & CEO, will present at
the Jesup & Lamont 2009 Growth Stock Conference organized by
the LifeTech Capital Group on Thursday, July 30, 2009 at 10:45 am
EDT. The presentation will occur live and will be held at the
Waldorf Astoria Boca Beach Club in Boca Raton, Florida.
"We are pleased to have the opportunity to present Access
Pharmaceuticals to the large group of institutional and retail
investors that attend Jesup's annual growth stock conference,"
stated Jeffrey B. Davis, Access' President & CEO. "The
conference provides a forum for Access to highlight in many product
programs, and specifically the very significant and positive
initial results and feedback from the commercial launch of MuGard,
our FDA approved treatment for oral mucositis. Initial clinical
feedback and experience exceeds our expectations."
About Access: Access Pharmaceuticals, Inc. is an emerging
biopharmaceutical company that develops and commercializes
propriety products for the treatment and supportive care of cancer
patients. Access' products include ProLindac(TM), currently in
Phase 2 clinical testing of patients with ovarian cancer, and
MuGard(TM) for the management of patients with mucositis. The
company also has other advanced drug delivery technologies
including Cobalamin(TM)-mediated targeted delivery and oral drug
delivery, its proprietary nanopolymer delivery technology based on
the natural vitamin B12 uptake mechanism; Angiolix , a humanized
monoclonal antibody which acts as an anti-angiogenesis factor and
is targeted to breast cancer; and Thiarabine, a new generation
nucleoside analog which has demonstrated both pre-clinical and
clinical activity in certain cancers. For additional information on
Access Pharmaceuticals, please visit our website at
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended, and that involve risks and uncertainties.
These statements include those relating to: clinical trial plans
and timelines and clinical results for ProLindac and product
candidates acquired in the MacroChem transaction, our ability to
execute licensing agreements in the future, Access' plans to
continue and initiate clinical trials, the value of its products in
the market (including MuGard and the size of the overall market for
mucositis products), its ability to achieve clinical and commercial
success and its ability to successfully develop marketed products.
These statements are subject to numerous risks, including but not
limited Access' need to obtain additional financing in order to
continue the clinical trial and operations and to the risks
detailed in Access' Annual Reports on Form 10-K and other reports
filed by Access with the Securities and Exchange Commission.
Source: Access Pharmaceuticals, Inc.
CONTACT: Company, Stephen B. Thompson, Vice President, Chief
Officer of Access Pharmaceuticals, Inc., +1-214-905-5100; Investor Relations,
Donald C. Weinberger or Diana Bittner (media), both of Wolfe Axelrod
Weinberger Assoc. LLC, +1-212-370-4500, for Access Pharmaceuticals, Inc.
Web Site: http://accesspharma.com/index.shtml
Posted: July 2009